Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Feb 1, 2012
SAN DIEGO, CA, and WOODCLIFF LAKE, NJ, February 1, 2012 - Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today that the US Food and Drug Administration (FDA) has notified...
-
Jan 30, 2012Two Innovative Programs Will Help Eliminate Lymphatic Filariasis By 2020
Tokyo, Japan, January 30, 2012 -- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai"), as one of the thirteen major research and development-based pharmaceutical...
-
Jan 10, 2012
SAN DIEGO and WOODCLIFF LAKE, N.J., Jan. 10, 2012 -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today that the US Food and Drug Administration (FDA) has accepted for...
-
Jan 9, 2012
Exton, PA, January 9, 2012 -- Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has entered into two agreements with Fox Chase Cancer Center ("Fox Chase") in Philadelphia, PA...
-
Jan 3, 2012
SAN DIEGO, CA, and WOODCLIFF LAKE, NJ, January 3, 2012 - Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today that Arena has submitted its response to the Complete Response...
-
Jan 3, 2012
Woodcliff Lake, NJ, January 3, 2012 — Eisai Inc. announced today that the Centers for Medicare and Medicaid Services (CMS) has assigned a unique, permanent Healthcare Common Procedure Coding...
-
Dec 26, 2011
Woodcliff Lake, NJ, December 26, 2011 - Eisai Inc. announced today that it resubmitted the New Drug Application (NDA) for the investigational AMPA-type glutamate receptor antagonist perampanel for...
-
Dec 15, 2011
Tokyo, Japan, December 15, 2011 -- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that its Canadian pharmaceutical sales subsidiary Eisai Limited...
-
Dec 2, 2011
Morphotek, a subsidiary of Eisai Inc., has decided to terminate FAR122, a study of its investigational agent farletuzumab (MORAb-003), in platinum-resistant ovarian cancer. This decision was based...
-
Dec 2, 2011Aims to Provide Personalized Medicine by Integrating Next-generation Synthetic Organic Chemistry with Patient-Based Cancer Genetics
Tokyo, Japan, December 2, 2011 -- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, ("Eisai") announced today that the company's U.S. research subsidiary H3 Biomedicine...
-
Dec 1, 2011
Tokyo, Japan, December 1, 2011 -- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that its Canadian pharmaceutical sales subsidiary Eisai Limited...
-
Nov 8, 20112011 C.A.R.E. (Commitment to Alzheimer's. Recognition of Excellence.) Pharmacy Award Acknowledges Excellence in Alzheimer's Disease Education and Patient Care
WOODCLIFF LAKE, NJ, November 8, 2011 - Eisai Inc. and the Alzheimer's Association announce today that Max C. Brown, RPh is the recipient of the 2011 C.A.R.E. Pharmacy Award. Mr. Brown has been...
-
Oct 26, 2011Eisai Joins WIPO Sponsored Global Consortium for Neglected Tropical Disease Research and Development
October 26, 2011, Tokyo, Japan -- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, ("Eisai") announced today that it has joined WIPO Re:Search, a new global consortium...
-
Oct 25, 2011Funding made possible through the support of Eisai Inc.
Woodcliff Lake, NJ, October 25, 2011 - The Breast Cancer Research Foundation (BCRF) announced today that it has awarded a research grant to Daniel F. Hayes, MD, Director of the Breast Oncology...
-
Oct 17, 2011
Tokyo, Japan, October 17, 2011 -- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that it has entered into a neurological drug discovery research...
-
Sep 26, 2011
SAN DIEGO, CA, and WOODCLIFF LAKE, NJ, September [26], 2011 - Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today that new data analyses from the lorcaserin Phase 3 clinical...
-
Sep 23, 2011
Lugano, Switzerland and Woodcliff Lake, NJ, USA Sept. 23, 2011 - Helsinn Group and Eisai Inc. announced today that Helsinn has commenced a multi-centered Phase III clinical study program...
-
Sep 7, 2011Enters Collaborative Development Agreement with SFJ Pharmaceuticals for Anticancer Agent E7080 (lenvatinib)
Tokyo, Japan, September 7, 2011 -- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that it has entered into a collaborative development agreement with...
-
Sep 2, 2011
Woodcliff Lake, NJ , September 2, 2011 -- Eisai Inc. announced today that the company has decided to discontinue global development of rabeprazole sodium extended-release capsules, 50 mg. On...
-
Aug 30, 2011
Woodcliff Lake, NJ, August 30, 2011 - Results presented today of a Phase III pivotal study for the investigational compound perampanel for partial-onset seizures showed that perampanel, 8 mg and...
-
Aug 16, 2011Eisai Laboratorios, S. de R.L. de C.V. to Introduce Eisai's Medicines to People Living in Mexico
Woodcliff Lake, NJ, August 16, 2011 - Eisai Inc. and its parent company Eisai Co., Ltd. today announce the establishment of a subsidiary company in Mexico, which will be named Eisai Laboratorios,...
-
Aug 9, 2011Report to be Included in Response to Lorcaserin CRL
SAN DIEGO, CA, and WOODCLIFF LAKE, NJ, August 9, 2011 - Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today results from a Pathology Working Group's (PWG) re-adjudication...
-
Aug 2, 2011
SAN DIEGO and WOODCLIFF LAKE, N.J., Aug. 2, 2011 -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today the completion of a clinical study that measured lorcaserin...
-
Jul 29, 2011
Woodcliff Lake, NJ, July 29, 2011 - Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has issued a Refusal to File letter in response to the company's New Drug...
-
Jul 19, 2011
Tokyo, Japan, July 19, 2011 -- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") today announced the launch of its novel anticancer agent Halaven in Japan for the...